Meeting
2015 ASCO Annual Meeting
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Authors
Karim Fizazi
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France
Karim Fizazi , Neal D. Shore , Teuvo L. J. Tammela , Toni Sarapohja , Annamari Vuorela , Iris Kuss , Amir Snapir , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT02200614
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS5080)
DOI
10.1200/jco.2015.33.15_suppl.tps5080
Abstract #
TPS5080
Poster Bd #
68b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.
First Author: Karim Fizazi
Poster
2022 ASCO Annual Meeting
A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE).
First Author: Alicia K. Morgans
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2023 ASCO Annual Meeting
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
First Author: Rahul Raj Aggarwal